Since the effects of TAAR1 agonists on bipolar disorder may arise from biased regulation of GSK3β pathways, it would be insightful to investigate whether biased TAAR1 agonists could yield different behavioral outcomes in subsequent studies. Here, GSK3B is linked to bipolar disorder.